FY2029 Earnings Forecast for ELDN Issued By Leerink Partnrs

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) – Analysts at Leerink Partnrs issued their FY2029 earnings estimates for shares of Eledon Pharmaceuticals in a research report issued to clients and investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith anticipates that the company will earn ($0.50) per share for the year. The consensus estimate for Eledon Pharmaceuticals’ current full-year earnings is ($0.81) per share.

Eledon Pharmaceuticals (NASDAQ:ELDN) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.02).

A number of other equities analysts have also recently weighed in on ELDN. HC Wainwright restated a “buy” rating and set a $16.00 price objective on shares of Eledon Pharmaceuticals in a research report on Wednesday, November 20th. Guggenheim started coverage on shares of Eledon Pharmaceuticals in a research report on Tuesday, January 28th. They set a “buy” rating and a $9.00 price target for the company.

Eledon Pharmaceuticals Price Performance

Shares of NASDAQ:ELDN opened at $4.70 on Friday. The business’s 50 day moving average price is $4.40 and its 200-day moving average price is $3.60. Eledon Pharmaceuticals has a 1 year low of $1.52 and a 1 year high of $5.54. The firm has a market capitalization of $280.78 million, a price-to-earnings ratio of -2.34 and a beta of 0.79.

Institutional Trading of Eledon Pharmaceuticals

Several large investors have recently made changes to their positions in the company. Inspire Investing LLC acquired a new stake in Eledon Pharmaceuticals during the 4th quarter worth $802,000. Renaissance Technologies LLC lifted its stake in shares of Eledon Pharmaceuticals by 57.1% in the second quarter. Renaissance Technologies LLC now owns 136,773 shares of the company’s stock worth $361,000 after buying an additional 49,704 shares in the last quarter. Geode Capital Management LLC boosted its position in Eledon Pharmaceuticals by 9.7% during the third quarter. Geode Capital Management LLC now owns 378,058 shares of the company’s stock worth $942,000 after acquiring an additional 33,569 shares during the last quarter. Dimensional Fund Advisors LP purchased a new stake in Eledon Pharmaceuticals during the 2nd quarter valued at about $80,000. Finally, Kera Capital Partners Inc. acquired a new stake in Eledon Pharmaceuticals in the 4th quarter valued at about $106,000. 56.77% of the stock is currently owned by hedge funds and other institutional investors.

Eledon Pharmaceuticals Company Profile

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).